Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.

Niewiadomska H, Mirowski M, Stempień M, Błoński JZ, Czyz W, Switalska J, Matyga E, Hanausek M, Wierzbicki R.

Neoplasma. 2000;47(1):8-14.

PMID:
10870681
2.

Expression of c-erbB3 protein in primary breast carcinomas.

Naidu R, Yadav M, Nair S, Kutty MK.

Br J Cancer. 1998 Nov;78(10):1385-90.

4.
6.
7.

The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.

Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ.

Anticancer Res. 1996 Sep-Oct;16(5B):3141-7.

PMID:
8920782
8.

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

Schneider J, Rubio MP, Barbazán MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS.

J Natl Cancer Inst. 1994 Jun 1;86(11):850-5.

PMID:
7910219
9.

EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Löhrs U.

Breast Cancer Res Treat. 2003 May;79(2):187-98.

PMID:
12825853
10.
11.

Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.

Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR.

Biotech Histochem. 2008 Feb;83(1):5-14. doi: 10.1080/10520290701822436.

PMID:
18568671
12.

p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.

Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO.

Br J Cancer. 1992 Sep;66(3):583-8.

13.

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.

Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A.

J Pathol. 1996 May;179(1):31-8.

PMID:
8691341
14.
15.
16.

Image analysis (DNA ploidy) and expression of c-erb B-2 and p53 in imprint smears of breast cancer.

Malle D, Patakiouta F, Bousoulegas A, Karakitsos P, Destouni C.

Eur J Gynaecol Oncol. 2003;24(6):531-4.

PMID:
14658596
17.
18.

A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients.

Niewiadomska H, Mirowski M, Stempien M, Olborski B, Blonski JZ, Hanausek M, Wierzbicki R.

Neoplasma. 1998;45(4):216-22.

PMID:
9890664
19.

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID:
16835704
20.

Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?

Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z.

Neoplasma. 2007;54(4):334-41.

PMID:
17822324
Items per page

Supplemental Content

Write to the Help Desk